Clinical Trials in San Francisco

Showing 161-180 of 6,211 trials

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT02123758

The purpose of this study is to investigate potential drug-drug interaction (DDI) between JNJ-56021927 and abiraterone acetate and between JNJ-56021927 and prednisone, determine safety of the combination and evaluate in a descriptive manner the efficacy in these participants. It will also, potentially provide dosing recommendations for abiraterone acetate in future studies when combined with JNJ-56021927.

Prostatic NeoplasmsMetastatic Castration-Resistant Prostate Cancer

Aragon Pharmaceuticals, Inc.57 participantsStarted Jul 2014

Los Angeles, California, United States • San Francisco, California, United States • Houston, Texas, United States +4 more locations

RECRUITINGPHASE3< 1 mile

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

NCT06631287

The overarching goal of this study is to determine if baricitinib, as compared to placebo, will improve neurocognitive function, along with measures of physical function, quality of life, post-exertional malaise, effect of breathlessness on daily activities, post-COVID-19 symptom burden, and biomarkers of inflammation and viral measures, in participants with Long COVID.

Long COVIDSars-CoV-2 InfectionCoronavirus Infections+1 more

Wes Ely550 participantsStarted Oct 2024

Tucson, Arizona, United States • Los Angeles, California, United States • San Francisco, California, United States +13 more locations

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

Find Trials by Condition in San Francisco

Guaranteed Income to Boost HIV Care Continuity and Suppression Post-Jail Release

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia

Evaluation of D-Fi for the Treatment of Wounds Due to DEB

Targeting Aging With a Ketone Ester for Function in Frailty

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy